 
										

20 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251020795690/en/Enanta-Pharmaceuticals-Presents-New-Data-for-Zelicapavir-its-N-Protein-Inhibitor-and-EDP-323-its-L-Protein-Inhibitor-Both-in-Development-for-the-Treatment-of-Respiratory-Syncytial-Virus-RSV-at-IDWeek-2025

07 Oct 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-10-07/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-fo

26 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250926821731/en/Enanta-Pharmaceuticals-to-Present-Topline-Results-from-its-Phase-2b-Study-Evaluating-Zelicapavir-for-the-Treatment-of-Respiratory-Syncytial-Virus-RSV-in-High-Risk-Adults

22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522937132/en/Enanta-Pharmaceuticals-Announces-Data-from-its-Phase-2-Study-of-Zelicapavir-in-Children-with-Respiratory-Syncytial-Virus-to-be-Presented-at-the-43rd-Annual-ESPID-Meeting